Everything you need to know about Pfizer's COVID-19 vaccine
Pfizer’s CEO says the findings bring us closer to a breakthrough in the fight against the coronavirus pandemic. But critics warn that the study still hasn’t been peer-reviewed and safety data has yet to be released.
This week, as COVID-19 cases continue to climb across the country, there is a glimmer of hope for returning to normal life: a vaccine.
Pharmaceutical companies Pfizer and BioNTech say that results from a Phase 3 study of their vaccine candidate look promising and that immunity could last a year.
Today, we hear from CBC science and technology reporter Emily Chung on what we know about the Pfizer-BioNTech vaccine that early results show is 90 per cent effective in preventing COVID-19.